Abstract:ID 93099 Poster Board 548 Background/Objective: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, whereas over 300 million individuals suffer from asthma worldwide. Cigarette smoking is recognized as the major risk factor in COPD and asthma patients who smoke often have poorly controlled disease. Glucocorticoids (GC) are the most effective anti-inflammatory drugs available. However, COPD and refractory severe asthma are frequently resistant to glucocorticoid therapy, thus posing an unmet need for better therapies. Although immune cells have been used to investigate glucocorticoid insensitivity (GCI), airway smooth muscle (ASM) cells have emerged as key contributors not only to airway hyperresponsiveness (AHR) but also to airway inflammation in patients with COPD and severe asthma. The objective of this study was to investigate effects of cigarette smoke exposure on glucocorticoid sensitivity of ASM cells. Hypothesis: Cigarette smoking exposure renders ASM cells insensitive to glucocorticoid transactivation. Methods: Primary human ASM cells derived from healthy controls and asthma patients were treated with various concentrations of cigarette smoking extract (CSE) for 24 h or two weeks. GC transactivation was measured using a Glucocorticoid Response Element (GRE)-driven luciferase reporter assay and measuring GC-inducible gene expression by qRT-PCR. Single-cell RNA sequencing was performed to identify differentially expressed genes (DEGs) in HASM cells and confirmed by qRT-PCR. Twenty normal nonsmoking subjects were enrolled as controls, with screening FEV1> 80% predicted. Forty current smokers were also enrolled, divided into subjects who demonstrated AHR, with a positive methacholine challenge (n = 20) versus those without AHR (n = 20). DEGs expression from peripheral blood mononuclear cells (PBMC) in chronic smokers, with and without AHR were determined by western blot assays. Data are presented as the mean ± SEM. P <0.05 is considered to be statistically significant. Results: CSE treatment for 24 h impaired GRE activation and the GC induction of several anti-inflammatory genes in multiple HASM cell lines in a dose-dependent manner with 70% reduction in 5% CSE-treated HASM cells. Chronic treatment with 2.5% CSE caused transcriptomic changes in HASM cells including Regulator of G Protein Signaling 2 (RGS2), a key regulator of ASM hypercontraction and AHR in asthma. Importantly, the GC dexamethasone enhanced β2-agonist albuterol-induced RGS2 expression in HASM cells, which was also impaired in CSE-treated HASM cells. In addition, RGS2 protein expression was significantly reduced in PBMC from chronic smokers without AHR, and to a greater degree in smokers with AHR, versus non-smokers. Conclusions: Our results indicate that CSE exposure not only profoundly impairs GC transactivation but also abolished dexamethasone and β2-agonist-induced RGS2 protein expression in HASM cells. Since RGS2 upregulation is a genomic mechanism of β2 - agonist-induced bronchoprotection that is enhanced by GC, our study suggests ASM as an important target for glucocorticoid therapy and may contribute to cigarette smoking-related GC insensitivity seen in patients with COPD and severe asthma.

Effects of Glucocorticoid-Induced Transcript 1 Gene Deficiency on Glucocorticoid Activation in Asthmatic Mice

GLCCI1 Deficiency Induces Glucocorticoid Resistance Via the Competitive Binding of IRF1:GRIP1 and IRF3:GRIP1 in Asthma

Glucocorticoids Modulate Th1 and Th2 Responses in Asthmatic Mouse Models by Inhibition of Notch1 Signaling

Glucocorticoid Induced Transcript 1 Represses Airway Remodeling of Asthmatic Mouse Via Inhibiting IL-13/periostin/TGF-β1 Signaling.

The GLCCI1 Rs37973 Variant and the Efficacy of Inhaled Corticosteroids in the Treatment of Asthma: A Meta-Analysis.

Effect of Inhaled Glucocorticoid on HMGB1 and IL-1β Expression in the Lungs of Asthmatic Mice

GLCCI1 Rs37973 is Associated with the Response of Adrenal Hormone to Inhaled Corticosteroids in Asthma

Cross‐talk between pro‐inflammatory transcription factors and glucocorticoids

Cigarette Smoke Exposure and Glucocorticoid Insensitivity of Airway Smooth Muscle Cells

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration

Inhibition of γ-glutamyl transferase suppresses airway hyperresponsiveness and airway inflammation in a mouse model of steroid resistant asthma exacerbation

GLCCI1 reduces collagen deposition and airway hyper‐responsiveness in a mouse asthma model through binding with WD repeat domain 45B

GLCCI1 Variation is Associated with Asthma Susceptibility and Inhaled Corticosteroid Response in a Chinese Han Population

The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma

Impact of ozone exposure on the response to glucocorticoid in a mouse model of asthma: involvements of p38 MAPK and MKP-1

Effect of inhaled glucocorticoid and leukotriene receptor on IL-6 expression in the lungs of asthmatic mice

Effects of Glucocorticoid and Cysteinyl Leukotriene 1 Receptor Antagonist on CD(34+) Hematopoietic Cells in Bone Marrow of Asthmatic Mice.

Chronic Intermittent Hypoxia Reduces the Effects of Glucosteroid in Asthma Via Activating the P38 MAPK Signaling Pathway

CTNNAL1 Enhances Glucocorticoid Sensitivity in HDM-induced Asthma Mouse Model Through Deactivating Hsp90 Signaling Pathway.

Steroid-Insensitive Gene Expression of Extracellular Matrix Components and Pro-fibrotic Factors in the Lung Associated with Airway Hyperresponsiveness in Murine Asthma

Research on relationship between GLCCI1 polymorphism and effect of inhaled corticosteroids in children with asthma